Clinical Trials
89 trialsA Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Corbus Pharmaceuticals Inc.
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Novartis
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Novartis
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
COMBI-i
Novartis
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus Inc.
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
HRYZ Biotech Co.
NEO-MIMAJOR
Biocad
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
TriSalus Life Sciences, Inc.
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Novartis
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
Corbus Pharmaceuticals Inc.
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Pfizer
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Novartis
KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors
Novartis
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
IT-01
Intensity Therapeutics, Inc.
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
HotSpot Therapeutics, Inc
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
Pfizer
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
MODULATE
Immodulon Therapeutics Ltd
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Novartis
A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Novartis
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
Novartis
A Study of CS1002 in Subjects with Advanced Solid Tumors
CStone Pharmaceuticals
Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
Energenx Medical LTD.
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
Symphogen A/S
Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Novartis
PLATforM
Novartis
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Jounce Therapeutics, Inc.
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Highlight Therapeutics
A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
Novartis
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd.